173 related articles for article (PubMed ID: 23864843)
21. Efficacy of post‑mastectomy radiotherapy in patients with T1‑2N1 breast cancer aged ≤35 years or with a positive HER‑2 status.
Wang M; Wang Y; Xie F; Ren H; Chen J; Wang Z
Mol Clin Oncol; 2023 Jul; 19(1):58. PubMed ID: 37359715
[TBL] [Abstract][Full Text] [Related]
22. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era.
Miyashita M; Tada H; Suzuki A; Watanabe G; Hirakawa H; Amari M; Kakugawa Y; Kawai M; Furuta A; Sato K; Yoshida R; Ebata A; Sasano H; Jingu K; Ohuchi N; Ishida T
Surg Oncol; 2017 Jun; 26(2):163-170. PubMed ID: 28577722
[TBL] [Abstract][Full Text] [Related]
23. The role of clinicopathologic and molecular prognostic factors in the post-mastectomy radiotherapy (PMRT): a retrospective analysis of 912 patients.
Ursino S; Fiorica F; Mazzotti V; Delishaj D; Cristaudo A; Spagnesi S; Laliscia C; Pasqualetti F; Fontana A; Ghilli M; Morganti R; Falcone A; Roncella M; Paiar F
Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2157-2166. PubMed ID: 28537668
[TBL] [Abstract][Full Text] [Related]
24. The prognostic differences and the effect of postmastectomy radiotherapy between post-chemotherapy ypT1-2ypN1 and de novo pT1-2N1 breast cancer.
Yang T; Zhong X; Wang J; Xiang Z; Zeng Y; Yu S; Dai Z; Xu N; Luo T; Liu L
Cancer Med; 2023 Apr; 12(7):8112-8121. PubMed ID: 36734308
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes.
Li Q; Wu S; Zhou J; Sun J; Li F; Lin Q; Guan X; Lin H; He Z
Curr Oncol; 2014 Oct; 21(5):e685-90. PubMed ID: 25302039
[TBL] [Abstract][Full Text] [Related]
26. The effects of ECE on the benefits of PMRT for breast cancer patients with positive axillary nodes.
Geng W; Zhang B; Li D; Liang X; Cao X
J Radiat Res; 2013 Jul; 54(4):712-8. PubMed ID: 23392824
[TBL] [Abstract][Full Text] [Related]
27. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
28. Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.
Abi-Raad R; Boutrus R; Wang R; Niemierko A; Macdonald S; Smith B; Taghian AG
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e151-7. PubMed ID: 21420245
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
Zhao JM; An Q; Sun CN; Li YB; Qin ZL; Guo H; Zeng X; Zhang YT; Wei LL; Han N; Sun SC; Zhang N
Breast Cancer; 2021 Mar; 28(2):298-306. PubMed ID: 32940902
[TBL] [Abstract][Full Text] [Related]
30. The effect of postmastectomy radiation therapy on high-risk patients with T1-2N0 breast cancer.
Luo C; Zhong X; Fan Y; Wang C; Wang Y; Luo T
Breast; 2021 Dec; 60():1-5. PubMed ID: 34455226
[TBL] [Abstract][Full Text] [Related]
31. The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection.
Mukesh MB; Duke S; Parashar D; Wishart G; Coles CE; Wilson C
Radiother Oncol; 2014 Mar; 110(3):461-6. PubMed ID: 24424386
[TBL] [Abstract][Full Text] [Related]
32. The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype.
Wei J; Jiang Y; Shao Z
Breast; 2020 Jun; 51():40-49. PubMed ID: 32200207
[TBL] [Abstract][Full Text] [Related]
33. The Role of Post-Mastectomy Radiotherapy in T1-2N1 Breast Cancer Patients: Propensity Score Matched Analysis.
Kim K; Park W; Kim H; Cho WK; Kim N; Nam SJ; Kim SW; Lee JE; Yu J; Chae BJ; Lee SK; Ryu JM
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001733
[TBL] [Abstract][Full Text] [Related]
34. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
[TBL] [Abstract][Full Text] [Related]
35. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer.
Lee JC; Truong PT; Kader HA; Speers CH; Olivotto IA
Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):623-9. PubMed ID: 16372488
[TBL] [Abstract][Full Text] [Related]
36. Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Zhang Y; Zhang Y; Liu Z; Qin Z; Li Y; Zhao J; Ma X; Yang Q; Han N; Zeng X; Guo H; Zhang N
J Oncol; 2021; 2021():6632635. PubMed ID: 33564308
[TBL] [Abstract][Full Text] [Related]
37. Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy.
Nagao T; Kinoshita T; Tamura N; Hojo T; Morota M; Kagami Y
Int J Clin Oncol; 2013 Feb; 18(1):54-61. PubMed ID: 22068463
[TBL] [Abstract][Full Text] [Related]
38. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
Fodor J; Polgár C; Major T; Németh G
Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of nomograms for predicting survival outcomes in patients with T1-2N1 breast cancer to identify those who could not benefit from postmastectomy radiotherapy.
Pu H; Luo Y; Zhang L; Li X; Li F; Chen J; Qian S; Tang Y; Zhao X; Hou L; Gao Y
Front Oncol; 2023; 13():1112687. PubMed ID: 37056328
[TBL] [Abstract][Full Text] [Related]
40. A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancer.
Sittenfeld SMC; Zabor EC; Hamilton SN; Kuerer HM; El-Tamer M; Naoum GE; Truong PT; Nichol A; Smith BD; Woodward WA; Moo TA; Powell SN; Shah CS; Taghian AG; Abu-Gheida I; Tendulkar RD
Cancer; 2022 Aug; 128(16):3057-3066. PubMed ID: 35713598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
